Ralph Stadhouders1, Bobby W S Li2, Marjolein J W de Bruijn2, Antonio Gomez3, Tata Nageswara Rao4, Hans Jörg Fehling4, Wilfred F J van IJcken5, Ai Ing Lim6, James P Di Santo6, Thomas Graf3, Rudi W Hendriks7. 1. Department of Pulmonary Medicine, Erasmus MC Rotterdam, The Netherlands; Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address: r.stadhouders@erasmusmc.nl. 2. Department of Pulmonary Medicine, Erasmus MC Rotterdam, The Netherlands. 3. Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. 4. Institute of Immunology, University Clinics, Ulm, Germany. 5. Center for Biomics, Erasmus MC Rotterdam, The Netherlands. 6. Innate Immunity Unit, Institut Pasteur, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U1223, Paris, France. 7. Department of Pulmonary Medicine, Erasmus MC Rotterdam, The Netherlands. Electronic address: r.hendriks@erasmusmc.nl.
Abstract
BACKGROUND: Group 2 innate lymphoid cells (ILC2s) are major producers of the cytokines driving allergic asthma, and increased ILC2 numbers have been detected in blood and sputum of asthmatic patients. Asthma susceptibility has a strong genetic component, but the underlying mechanisms and whether asthma genetics affect ILC2 biology remain unclear. OBJECTIVE: We sought to study the ILC2 transcriptome and epigenome during airway inflammation (AI) to couple these to genes and genetic variants associated with asthma pathogenesis. METHODS: Mice harboring a reporter for the key ILC2 transcription factor GATA-3 were subjected to IL-33-driven AI, and ILC2s were isolated from bronchoalveolar lavage fluid and mediastinal lymph nodes. Human ILC2s were purified from peripheral blood and activated in vitro. We used RNA sequencing, genome-wide identification of histone-3 lysine-4 dimethylation-marked chromatin, and computational approaches to study the ILC2 transcriptome and epigenome. RESULTS: Activated ILC2s in mice displayed a tissue-specific gene expression signature that emerged from remarkably similar epigenomes. We identified superenhancers implicated in controlling ILC2 identity and asthma-associated genes. More than 300 asthma-associated genetic polymorphisms identified in genome-wide association studies localized to H3K4Me2+ gene regulatory elements in ILC2s. A refined set of candidate causal asthma-associated variants was uniquely enriched in ILC2, but not TH2 cell, regulatory regions. CONCLUSIONS: ILC2s in AI use a flexible epigenome that couples adaptation to new microenvironments with functional plasticity. Importantly, we reveal strong correlations between gene regulatory mechanisms in ILC2s and the genetic basis of asthma, supporting a pathogenic role for ILC2s in patients with allergic asthma.
BACKGROUND: Group 2 innate lymphoid cells (ILC2s) are major producers of the cytokines driving allergic asthma, and increased ILC2 numbers have been detected in blood and sputum of asthmatic patients. Asthma susceptibility has a strong genetic component, but the underlying mechanisms and whether asthma genetics affect ILC2 biology remain unclear. OBJECTIVE: We sought to study the ILC2 transcriptome and epigenome during airway inflammation (AI) to couple these to genes and genetic variants associated with asthma pathogenesis. METHODS:Mice harboring a reporter for the key ILC2 transcription factor GATA-3 were subjected to IL-33-driven AI, and ILC2s were isolated from bronchoalveolar lavage fluid and mediastinal lymph nodes. Human ILC2s were purified from peripheral blood and activated in vitro. We used RNA sequencing, genome-wide identification of histone-3 lysine-4 dimethylation-marked chromatin, and computational approaches to study the ILC2 transcriptome and epigenome. RESULTS: Activated ILC2s in mice displayed a tissue-specific gene expression signature that emerged from remarkably similar epigenomes. We identified superenhancers implicated in controlling ILC2 identity and asthma-associated genes. More than 300 asthma-associated genetic polymorphisms identified in genome-wide association studies localized to H3K4Me2+ gene regulatory elements in ILC2s. A refined set of candidate causal asthma-associated variants was uniquely enriched in ILC2, but not TH2 cell, regulatory regions. CONCLUSIONS: ILC2s in AI use a flexible epigenome that couples adaptation to new microenvironments with functional plasticity. Importantly, we reveal strong correlations between gene regulatory mechanisms in ILC2s and the genetic basis of asthma, supporting a pathogenic role for ILC2s in patients with allergic asthma.
Authors: Irma Tindemans; Anne van Schoonhoven; Alex KleinJan; Marjolein Jw de Bruijn; Melanie Lukkes; Menno van Nimwegen; Anouk van den Branden; Ingrid M Bergen; Odilia Bj Corneth; Wilfred Fj van IJcken; Ralph Stadhouders; Rudi W Hendriks Journal: J Clin Invest Date: 2020-07-01 Impact factor: 14.808
Authors: Esmee K van der Ploeg; Ana Carreras Mascaro; Danny Huylebroeck; Rudi W Hendriks; Ralph Stadhouders Journal: J Innate Immun Date: 2019-02-06 Impact factor: 7.349
Authors: Clare M Williams; Sreeja Roy; Danielle Califano; Andrew N J McKenzie; Dennis W Metzger; Yoichi Furuya Journal: J Virol Date: 2021-09-01 Impact factor: 5.103
Authors: J A Tuazon; B Kilburg-Basnyat; L M Oldfield; R Wiscovitch-Russo; K Dunigan-Russell; A V Fedulov; K J Oestreich; K M Gowdy Journal: Curr Allergy Asthma Rep Date: 2022-04-08 Impact factor: 4.919
Authors: Michael D Weiden; Ankura Singh; David G Goldfarb; Barbara Putman; Rachel Zeig-Owens; Theresa Schwartz; Hillel W Cohen; David J Prezant Journal: Am J Ind Med Date: 2021-07-20 Impact factor: 3.079